{"filings":[{"id":705036,"accession_number":"0001388658-26-000049","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-05-28T11:33:42+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"iRhythm shareholders approve 2026 equity plan, elect directors, remove pass-through voting provision","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected with strong support; no broker votes on most proposals.","2026 Equity Incentive Plan approved (26.8M for, 537K against), replacing the 2016 Plan.","Charter amendment to eliminate pass-through voting provision approved (27.3M for, 21.4K against).","KPMG ratified as FY2026 auditor (29.4M for, 16.8K against); say-on-pay approved non-binding.","Approximately 89.69% of outstanding shares represented, forming quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92561,"accession_number":"0001388658-26-000038","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q1 revenue $199.4M (+25.7%), net loss narrows; raises FY2026 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $199.4M, up 25.7% YoY; net loss $13.9M ($0.43/sh) vs $30.7M ($0.97/sh) in Q1 2025.","Adjusted EBITDA turned positive at $14.1M (7.1% margin) vs -$2.6M (-1.7%) a year ago; gross margin 70.9% up 210bps.","Raised FY2026 revenue guidance to $875M-$885M and adjusted EBITDA margin to 12%-13%.","Unrestricted cash $549.6M; presented data at ACC/HRS and launched new digital education platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":199390000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92560,"accession_number":"0001388658-26-000022","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"iRhythm dismisses PwC as auditor, hires KPMG for FY2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed PricewaterhouseCoopers LLP as independent auditor on March 30, 2026.","Audit reports for FY2024 and FY2025 contained no adverse opinion or modification.","Engaged KPMG LLP as new independent auditor for FY2026, effective March 30, 2026.","No disagreements or reportable events between PwC and the Company in the past two fiscal years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103485,"accession_number":"0001388658-26-000017","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"iRhythm appoints Jason Patten to board; $300K RSU grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Patten appointed director and Audit Committee member effective March 12, 2026.","Initial restricted stock unit grant valued at $300,000, vesting over three years.","Annual cash retainer of $55,000 for board service plus $10,000 for Audit Committee.","Patten previously served as advisor to CEO, receiving a one-time cash payment of $86,771.","Board determined Patten qualifies as independent under Nasdaq and SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103484,"accession_number":"0001388658-26-000009","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm posts Q4 net income of $5.6M; first positive GAAP quarter; revenue +27% YoY; guides FY26 rev $870-880M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $208.9M (+27.1% YoY); GAAP net income $5.6M ($0.17 diluted EPS), first positive quarterly net income in company history.","Full year 2025 revenue $747.1M (+26.2%); net loss improved to $44.6M from $113.3M; first positive free cash flow of $34.5M.","Q4 adjusted EBITDA $34.3M (16.4% margin) vs $19.3M (11.7% margin) in Q4 2024; gross margin 70.9% (+90 bps).","FY2026 guidance: revenue $870-880M, adjusted EBITDA margin 11.5-12.5%.","Cash and marketable securities $583.8M at Dec 31, 2025; record quarterly revenue and fifth consecutive quarter >20% growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":747138000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103486,"accession_number":"0001104659-26-002755","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K12B","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.03","3.01","3.03","5.01","5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"iRhythm completes holding company reorganization; new parent iRhythm Holdings successor issuer under IRTC","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Formed new parent iRhythm Holdings via merger of iRhythm into wholly owned sub; no stockholder vote required under DGCL Section 251(g).","Each share of iRhythm common stock converted 1:1 into iRhythm Holdings common stock; same ticker IRTC and CUSIP.","Executive officers and directors remain unchanged; equity awards and convertible notes assumed by iRhythm Holdings with adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119736,"accession_number":"0001388658-25-000219","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iRhythm issues fall 2025 shareholder outreach presentation; no material new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished investor presentation as part of off-season proxy engagement program.","Presentation dated November 2025; no specific financial or operational updates provided in the filed exhibit excerpt.","Filing under Regulation FD; presentation is furnished, not filed.","No changes to guidance, strategy, or leadership were communicated in the available material."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119735,"accession_number":"0001388658-25-000216","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","5.02","2.02","9.01"],"status":"ready","headline":"iRhythm Q3 beat: rev $192.9M up 31% YoY, net loss narrows to $5.2M; FY25 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $192.9M, up 30.7% YoY; gross margin 71.1% (+230bps).","Net loss of $5.2M ($0.16 diluted loss per share) vs $46.2M loss in Q3 2024.","Adjusted net loss $2.0M ($0.06 per share) vs $39.2M ($1.26) prior year.","FY2025 revenue guidance raised to $735M-$740M; adj. EBITDA margin 8.25-8.75%.","Board amended exec severance policy: enhanced change-of-control benefits; CEO gets 24 mo salary + 200% bonus + full equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":538248000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136309,"accession_number":"0001388658-25-000194","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q2 revenue up 26.1% to $186.7M; net loss narrows to $14.2M; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $186.7M (+26.1% YoY); gross margin 71.2% (+130 bps).","Net loss $14.2M ($0.44/sh) improved from $20.1M loss ($0.65/sh) in Q2 2024.","Adjusted net loss $10.2M ($0.32/sh) improved from $18.8M loss ($0.61/sh) YoY.","FY 2025 guidance raised: revenue $720M-$730M; adj. EBITDA margin 8.0%-8.5%.","Unrestricted cash $545.5M; partnership with Lucem Health for AI-driven early disease detection."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":345364000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136308,"accession_number":"0001388658-25-000177","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"iRhythm board: Rubash and Snyderman retire; McGinnis and O'Boyle appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mark Rubash (board since 2016) and Ralph Snyderman (board since 2017) resigned effective July 7, 2025; no disagreement cited.","Karen McGinnis and Kevin O'Boyle appointed as directors effective July 7, 2025, both also join Audit Committee; O'Boyle also on Nominating & Governance.","Each new director granted RSUs with $300,000 fair value vesting over 3 years; annual cash retainers of $55k (board), $10k (audit), and $5k (governance for O'Boyle).","Board determined both new appointees qualify as independent under Nasdaq and SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153429,"accession_number":"0001388658-25-000141","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"iRhythm shareholders elect all director nominees, ratify PwC as auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 30,038,591 shares (94.1% of eligible) present at May 28, 2025 annual meeting.","All eight director nominees elected: Blackford 28.2M for, Talwalkar 26.8M for, Bairey Merz 28.0M for, Bodaken 21.8M for, Ling 28.2M for, Rubash 27.5M for, Snyderman 28.1M for, Yoor 28.4M for.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2025: 29,903,062 for, 132,424 against, 3,105 abstentions.","Advisory vote on named executive officer compensation approved: 27,454,502 for, 382,813 against, 774,141 abstentions.","All proposals passed with substantial majority; broker non-votes of 1,427,135 on director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153428,"accession_number":"0001388658-25-000105","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q1 revenue up 20% to $158.7M; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $158.7M (+20.3% YoY); gross margin 68.8% (+250 bps).","Net loss narrowed to $30.7M ($0.97 diluted EPS) from $45.7M ($1.47) last year.","Adjusted net loss $30.3M ($0.95 diluted EPS) vs $38.1M ($1.23) in Q1 2024.","Cash $520.6M; raised FY25 revenue guidance to $690–700M and adj. EBITDA margin to 7.5–8.5%.","Operational: Zio AT strength, Japan commercial launch, studies showing LTCM superiority."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":158677000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172174,"accession_number":"0001388658-25-000026","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q4 revenue up 24% to $164.3M; net loss narrows to $1.3M; guides FY2025 revenue $675-685M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $164.3M (+24% YoY); gross margin 70.0% (+410bps). Net loss $1.3M vs $38.7M loss in Q4 2023.","Full year 2024 revenue $591.8M (+20.1%); net loss $113.3M vs $123.4M in 2023.","Adjusted EBITDA Q4 $19.3M (improvement of $16.9M); FY2024 adj EBITDA $(7.7)M.","Cash and marketable securities $535.6M at Dec 31, 2024; positive cash flow for three consecutive quarters.","2025 guidance: revenue $675-685M; adj EBITDA margin 7-8% of revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":591839000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172173,"accession_number":"0001388658-25-000005","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Mojdeh Poul to not seek re-election to iRhythm board at next annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mojdeh Poul notified iRhythm she will not stand for re-election when her current term expires.","Term ends on the date of the company's next annual meeting of stockholders.","Poul was recently appointed President and CEO of Integra LifeSciences (effective Jan 6, 2025).","Poul confirmed her decision is not based on any disagreement with iRhythm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172172,"accession_number":"0001388658-25-000003","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iRhythm pre-announces FY2024 revenue above guidance; FY2025 outlook $675M-$685M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2024 revenue expected slightly above prior guidance of $587.5M (provided Oct 2024).","FY2025 revenue guidance of $675M-$685M, representing ~15% growth at midpoint.","Record Q4 new account openings for Zio monitor and Zio AT; strong national account volumes.","First four health systems launched on Epic Aura in Q4 2024; commercial rollout for Epic systems starts 2025.","Began Zio monitor shipments for home enrollment patients in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189156,"accession_number":"0001388658-24-000176","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["1.01","5.02","5.05","9.01"],"status":"ready","headline":"iRhythm removes evergreen provision from 2016 equity plan, amends Code of Conduct","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to 2016 Equity Incentive Plan removing automatic annual share increase (Evergreen Provision).","Maximum shares available for issuance as of Nov 7, 2024 is 5,169,736 plus shares from forfeited 2006 Plan awards.","Code of Conduct amended to modernize language, clarify manager responsibilities and policies on quality, privacy, security.","No waivers of prior Code provisions; revisions aim to support business and supply chain compliance.","Changes are governance-oriented; no financial impact from the plan amendment itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189155,"accession_number":"0001388658-24-000165","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q3 revenue $147.5M (+18% YoY); gross margin 68.8% up 260 bps","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $147.5M, up 18% YoY; gross profit $101.5M (+23%); gross margin 68.8% vs 66.2%","Record quarterly registration volume; record new account openings in US; UK billable registrations >10,000","FDA 510(k) clearance for Zio AT updates; commercial launch in Austria, Netherlands, Switzerland, Spain; Japan PMDA approval","Technology license agreement with BioIntelliSense for multi-sensor capabilities; recognized $32.1M IPR&D charge","Unrestricted cash $522.0M at Sep 30; cumulative one million patients registered for Zio monitor"],"consensus_eps_estimate":null,"consensus_eps_actual":-3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":427514000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189154,"accession_number":"0001388658-24-000159","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iRhythm issues shareholder engagement presentation; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation covers business overview, YTD accomplishments, governance, executive compensation, and sustainability.","No specific financial or operational metrics, guidance updates, or corporate events were disclosed.","Presentation is part of routine shareholder engagement program, not a material event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205638,"accession_number":"0001388658-24-000156","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"iRhythm licenses BioIntelliSense sensor tech for up to $35M + royalties; reaffirms FY2024 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["iRhythm pays $15M upfront and up to $20M in milestone payments for an exclusive ACM license of pulse oximetry, accelerometry, and non-invasive BP tech.","Also purchased $40M in convertible notes from BioIntelliSense; $20M of Milestone Notes will be cancelled upon regulatory milestones.","Low single-digit royalties on home sleep testing product sales; license expires 10 years after first commercial sale per country.","iRhythm expects a non-recurring acquired IPR&D expense in 2024 but no material additional development costs; FY2024 revenue, gross margin, and adjusted EBITDA guidance reaffirmed.","Deal aims to expand iRhythm's ACM platform and enable entry into sleep apnea and other adjacent indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205637,"accession_number":"0001388658-24-000140","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"iRhythm Q2 revenue $148M (+19.3% YoY), raises FY24 guidance; names new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $148.0M, up 19.3% YoY; gross margin 69.9% (+40 bps YoY).","Net loss $20.1M ($0.65 loss per share); adjusted net loss $18.8M ($0.61 per share).","Raised FY24 revenue guidance to $580-590M (18-20% growth); adj. EBITDA margin 3.5-4%.","CFO Brice Bobzien resigns effective Aug 31, 2024; succeeded by Daniel Wilson (EVP Corp Dev & IR)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":279976000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222573,"accession_number":"0001388658-24-000106","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"iRhythm say-on-pay vote fails with majority against; all 9 directors re-elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Say-on-pay advisory proposal on NEO compensation rejected: 13.8M for vs 14.5M against.","All nine director nominees elected (Blackford, Talwalkar, Bairey Merz, Bodaken, Ling, Poul, Rubash, Snyderman, Yoor).","Ratification of PwC as independent auditor approved: 29.7M for, 113,942 against.","Amendment to charter to limit officer liability approved: 26.0M for, 2.3M against.","Frequency of future say-on-pay votes set to one year: 27.9M votes for 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222572,"accession_number":"0001388658-24-000096","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q1 revenue $131.9M (+18.4% YoY); net loss widens to $45.7M; raises FY revenue guidance to $578-588M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $131.9M (+18.4% YoY); gross margin 66.3% (down 160 bps YoY).","Net loss $45.7M ($1.47/share) vs $39.1M ($1.29) YoY; adjusted loss $38.1M ($1.23) vs $33.4M ($1.10).","FY2024 revenue guidance raised to $578-588M (17-19% growth); gross margin 68-69%, adj. EBITDA margin 3-4%.","Over 500K registrations in Q1; announced Epic Aura collaboration for EMR integration; heart failure prediction data presented at ACC.","Unrestricted cash, equivalents, and marketable securities $569.1M as of March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":131929000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}